Systems, methods, compositions and solutions for perfusing an organ

• US 10,039,276 B2
• Filed: 06/09/2015
• Issued: 08/07/2018
• Est. Priority Date: 06/28/2005
• Status: Active Grant

• Current Assignee: TransMedics, Inc. (TransMedics Group, Inc.)
• Original Assignee: TransMedics, Inc. (TransMedics Group, Inc.)
• Inventors: Hassanein, Waleed H., Khayal, Tamer I., Lezberg, Paul
• Primary Examiner(s): Singh, Satyendra K
• Application Number:
  US14/734,769
• Publication Number:
  US 20150342176A1
• Time in Patent Office: 1,155 Days
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A01N 1/0226 Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
• CPC Class Codes: A01N 1/0247 for perfusion, i.e. for circulating fluid through organs, blood vessels or other living parts
• CPC Class Codes: C12M 21/08 for producing artificial tissue or for ex-vivo cultivation of tissue prostheses A61F2/00, grafts A61L27/00

Abstract

The invention, in various embodiments, provides systems, methods and solutions for perfusing an organ.

Claims

1. A perfusion system configured for maintaining an ex-vivo heart in a functioning state under physiological or near physiological conditions comprising:

a first chamber containing a first solution comprising one or more cardio stimulants selected from the group consisting of catecholamines, peptides, polypeptides, β

1/β

2-adrenoreceptor blocking agents, buplinarol, pindolol, alprenolol, cardiac glycosides, digitalis, palustrin, and ferulic acid; and

a plurality of amino acids selected from the group consisting of alanine, arginine, aspartic acid, glutamic acid, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and lysine that do not include asparagine, glutamine, and cysteine;

a second chamber containing a second solution comprising one or more carbohydrates selected from the group consisting of monosaccharides, disaccharides, oligosaccharides, and polysaccharides; and

a third chamber containing a priming solution comprising mannitol, sodium chloride, potassium chloride, magnesium sulfate heptahydrate, and sodium glycerophosphate.

2. The perfusion system of claim 1, wherein at least one of the first solution, second solution, or priming solution is sterilized prior to using the solutions to perfuse the heart.

3. The perfusion system of claim 1, wherein the one or more cardio stimulants includes epinephrine.

4. The perfusion system of claim 1, wherein the one or more carbohydrates in the second solution includes dextrose.

5. The perfusion system of claim 1, wherein the first solution includes adenosine.

6. The perfusion system of claim 1, wherein the first solution includes insulin.

7. The perfusion system of claim 1, wherein the first solution includes an immuno-suppressant.

8. The perfusion system of claim 1, wherein the first solution includes a multi-vitamin composition.

9. The perfusion system of claim 1, further comprising one or more electrolytes in the first solution.

10. The perfusion system of claim 9, wherein the one or more electrolytes includes calcium.

11. The perfusion system of claim 1, wherein the solutions are combined with a blood product prior to perfusing the heart.

12. The perfusion system of claim 1, further comprising a therapeutic agent.

13. A kit for use in a perfusion system that is configured for maintaining an ex-vivo heart in a functioning state under physiological or near physiological conditions, the kit comprising:

a first solution comprising one or more carbohydrates selected from the group consisting of monosaccharides, disaccharides, oligosaccharides, and polysaccharides,

a second solution comprising one or more cardio stimulants selected from the group consisting of catecholamines, peptides, polypeptides, δ

1/β

2-adrenoreceptor blocking agents, buplinarol, pindolol, alprenolol, cardiac glycosides, digitalis, palustrin, and ferulic acid; and

a plurality of amino acids selected from the group consisting of alanine, arginine, aspartic acid, glutamic acid, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and lysine that do not include asparagine, glutamine, and cysteine, and

a priming solution comprising mannitol, sodium chloride, potassium chloride, magnesium sulfate heptahydrate, and sodium glycerophosphate,

and a package.